Veloxis Pharma Inc v. Biocon Pharma Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Veloxis Pharmaceuticals, Inc. (Delaware)
  • Defendant: Biocon Pharma Limited (India)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:26-cv-00827, D. Del., 07/09/2026
• Venue Allegations: Venue is based on Defendant's alleged systematic and continuous contacts with Delaware, its business activities and revenue derived from Delaware, and its status as a foreign company.
• Core Dispute: Plaintiff alleges that Defendant's Abbreviated New Drug Application (ANDA) to market generic extended-release tacrolimus tablets infringes ten U.S. patents covering formulations and methods of use for the drug.
• Technical Context: The technology relates to formulations of tacrolimus, a critical immunosuppressant drug with a narrow therapeutic index used to prevent organ rejection in transplant patients.
• Key Procedural History: This action arises under the Hatch-Waxman Act, triggered by Defendant's submission of ANDA No. 221264 to the U.S. Food and Drug Administration (FDA). The ANDA contains Paragraph IV certifications asserting that the claims of the patents-in-suit are invalid, unenforceable, or will not be infringed by Defendant's proposed generic products.

Case Timeline

Date	Event
2007-05-30	Earliest Priority Date (all Patents-in-Suit)
2014-03-04	U.S. Patent No. 8,664,239 Issues
2014-04-01	U.S. Patent No. 8,685,998 Issues
2017-01-24	U.S. Patent No. 9,549,918 Issues
2019-01-01	U.S. Patent No. 10,166,190 Issues
2020-12-15	U.S. Patent No. 10,864,199 Issues
2021-09-07	U.S. Patent No. 11,110,081 Issues
2021-09-21	U.S. Patent No. 11,123,331 Issues
2022-08-23	U.S. Patent No. 11,419,823 Issues
2024-09-10	U.S. Patent No. 12,083,103 Issues
2025-09-02	U.S. Patent No. 12,403,095 Issues
2026-05-27	Date of Defendant's Paragraph IV Notice Letter
2026-07-09	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,664,239 - Tacrolimus for Improved Treatment of Transplant Patients

The Invention Explained

• Problem Addressed: The patent describes that conventional tacrolimus administration results in large inter- and intra-patient variability in absorption and metabolism, which makes standard dosing difficult and necessitates frequent blood monitoring to adjust dosage '239 Patent, col. 1:51-58 The absorption is also negatively affected by food '239 Patent, col. 2:20-22
• The Patented Solution: The patent claims a method of treatment using an extended-release oral dosage form of tacrolimus that releases the drug over a very prolonged period '239 Patent, col. 4:35-41 This controlled release is designed to improve bioavailability and create a more predictable pharmacokinetic profile, characterized by lower peak concentrations and a longer time to reach maximal concentration compared to immediate-release versions '239 Patent, abstract '239 Patent, col. 4:41-54 The specific release profile is defined by dissolution testing parameters, such as releasing no more than 63.5% of the drug at the 12-hour mark '239 Patent, col. 9:30-41
• Technical Importance: This approach enables a once-daily dosing regimen, which can improve patient compliance and safety by reducing side effects associated with high peak drug concentrations, such as nephrotoxicity and neurotoxicity '239 Patent, col. 4:15-24

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶44
• Claim 1 of the '239 Patent requires:
  • A method of providing immunosuppressive treatment of a patient in need thereof in a once daily regimen.
  • The method comprises orally administering an extended release tacrolimus formulation to the patient.
  • The formulation releases tacrolimus with a release of at the most 63.5% of the content of the tacrolimus at the 12 hours time point.
  • The release profile is determined when tested in vitro according to the USP II dissolution test (paddle) or USP I dissolution test (basket) in a specific medium (pH 4.5, 0.005% hydroxypropylcellulose) at a rotation of 50 rpm.
• The complaint does not explicitly reserve the right to assert dependent claims but makes a general allegation of infringement of "one or more claims" Compl. ¶44

U.S. Patent No. 8,685,998 - Tacrolimus for Improved Treatment of Transplant Patients

The Invention Explained

• Problem Addressed: Similar to the '239 Patent, this patent addresses the significant inter- and intra-individual variability in tacrolimus absorption and metabolism, which complicates dosing and requires frequent blood monitoring '998 Patent, col. 1:52-59
• The Patented Solution: The patent discloses a method of treatment using a once-daily, extended-release tacrolimus formulation that achieves a specific pharmacokinetic profile '998 Patent, abstract The key characteristic is a reduced peak plasma concentration (Cmax) that is at most about 80% of the Cmax observed with the conventional immediate-release Prograf® tablets, which is intended to reduce peak-related side effects while maintaining therapeutic efficacy '998 Patent, col. 11:50-59
• Technical Importance: By lowering the peak blood concentration, the formulation aims to reduce the incidence and severity of dose-dependent side effects like neuro- and nephro-toxicity, thereby improving the drug's safety profile '998 Patent, col. 13:15-20

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶55
• Claim 1 of the '998 Patent requires:
  • A method of providing immunosuppressive treatment of a patient in need thereof in a once daily regimen.
  • The method comprises orally administering an extended release tacrolimus formulation to the patient.
  • The formulation, upon oral administration, releases tacrolimus in a controlled manner.
  • The formulation exhibits a Cmax that is at the most about 80% of that of Cmax for Prograf® tablets administered under the same conditions.
• The complaint does not explicitly reserve the right to assert dependent claims but makes a general allegation of infringement of "one or more claims" Compl. ¶55

U.S. Patent No. 9,549,918 - Stabilized Tacrolimus Composition

• Patent Identification: U.S. Patent No. 9,549,918, Stabilized Tacrolimus Composition, issued January 24, 2017 Compl. ¶19
• Technology Synopsis: This patent addresses the chemical instability of tacrolimus in pharmaceutical formulations, which can lead to the formation of degradation products. The invention is a stable pharmaceutical composition of tacrolimus that includes a stabilizing agent, such as an organic acid, to prevent or reduce degradation '918 Patent, abstract
• Asserted Claims: At least claim 1 Compl. ¶66
• Accused Features: Defendant's generic tacrolimus formulation is alleged to be a stabilized composition that infringes Compl. ¶67

U.S. Patent No. 10,166,190 - Stabilized Tacrolimus Composition

• Patent Identification: U.S. Patent No. 10,166,190, Stabilized Tacrolimus Composition, issued January 1, 2019 Compl. ¶20
• Technology Synopsis: Similar to the '918 Patent, this patent is directed to stabilizing tacrolimus against degradation, particularly the formation of the 8-epitacrolimus isomer. The invention is a pharmaceutical composition comprising a solid dispersion of tacrolimus with a stabilizing agent capable of providing a pH below 7 '190 Patent, abstract
• Asserted Claims: At least claim 1 Compl. ¶77
• Accused Features: Defendant's generic tacrolimus formulation is alleged to be a stabilized composition that infringes Compl. ¶78

U.S. Patent No. 10,864,199 - Tacrolimus for Improved Treatment of Transplant Patients

• Patent Identification: U.S. Patent No. 10,864,199, Tacrolimus for Improved Treatment of Transplant Patients, issued December 15, 2020 Compl. ¶21
• Technology Synopsis: This patent claims a method of treatment using a once-daily, extended-release tacrolimus formulation. The invention is defined by a specific in vivo pharmacokinetic profile, including a reduced peak concentration (Cmax) and an extended time to reach it (Tmax) compared to immediate-release formulations '199 Patent, abstract
• Asserted Claims: At least claim 14 Compl. ¶88
• Accused Features: The use of Defendant's generic tacrolimus product is alleged to infringe the claimed method of treatment Compl. ¶89

U.S. Patent No. 11,110,081 - Tacrolimus for Improved Treatment of Transplant Patients

• Patent Identification: U.S. Patent No. 11,110,081, Tacrolimus for Improved Treatment of Transplant Patients, issued September 7, 2021 Compl. ¶22
• Technology Synopsis: This patent claims a method of treatment using a once-daily, extended-release tacrolimus formulation that achieves an improved pharmacokinetic profile. The claims focus on specific in vitro dissolution rates over an extended period to ensure controlled release, particularly in the colon '081 Patent, abstract '081 Patent, col. 9:30-41
• Asserted Claims: At least claim 1 Compl. ¶98
• Accused Features: The use of Defendant's generic tacrolimus product is alleged to infringe the claimed method of treatment Compl. ¶99

U.S. Patent No. 11,123,331 - Tacrolimus for Improved Treatment of Transplant Patients

• Patent Identification: U.S. Patent No. 11,123,331, Tacrolimus for Improved Treatment of Transplant Patients, issued September 21, 2021 Compl. ¶23
• Technology Synopsis: This patent is directed to a method of providing immunosuppressive treatment with an extended-release tacrolimus formulation. The invention is characterized by specific pharmacokinetic parameters, such as a Cmax that is at most 80% of that of the immediate-release drug Prograf®, to improve the safety profile '331 Patent, abstract
• Asserted Claims: At least claim 1 Compl. ¶108
• Accused Features: The use of Defendant's generic tacrolimus product is alleged to infringe the claimed method Compl. ¶109

U.S. Patent No. 11,419,823 - Stabilized Tacrolimus Composition

• Patent Identification: U.S. Patent No. 11,419,823, Stabilized Tacrolimus Composition, issued August 23, 2022 Compl. ¶24
• Technology Synopsis: This patent relates to a stable pharmaceutical composition containing tacrolimus. The invention utilizes a stabilizing agent, such as an organic acid, to prevent the formation of degradation products like 8-epitacrolimus upon storage '823 Patent, abstract
• Asserted Claims: At least claim 1 Compl. ¶118
• Accused Features: Defendant's generic tacrolimus formulation is alleged to be a stabilized composition that infringes Compl. ¶119

U.S. Patent No. 12,083,103 - Tacrolimus for Improved Treatment of Transplant Patients

• Patent Identification: U.S. Patent No. 12,083,103, Tacrolimus for Improved Treatment of Transplant Patients, issued September 10, 2024 Compl. ¶25
• Technology Synopsis: This patent claims a method of treatment using a once-daily, extended-release tacrolimus formulation. The invention is defined by its pharmacokinetic profile, which includes a reduced peak concentration and an extended time to maximum concentration to improve the drug's therapeutic index '103 Patent, abstract
• Asserted Claims: At least claim 1 Compl. ¶129
• Accused Features: The use of Defendant's generic tacrolimus product is alleged to infringe the claimed method of treatment Compl. ¶130

U.S. Patent No. 12,403,095 - Stabilized Tacrolimus Composition

• Patent Identification: U.S. Patent No. 12,403,095, Stabilized Tacrolimus Composition, issued September 2, 2025 Compl. ¶26
• Technology Synopsis: This patent is directed to a stable pharmaceutical composition of tacrolimus. The invention focuses on including a stabilizing agent in a solid dispersion to provide a pH below 7, which prevents or reduces the formation of degradation products during storage '095 Patent, abstract
• Asserted Claims: At least claim 1 Compl. ¶139
• Accused Features: Defendant's generic tacrolimus formulation is alleged to be a stabilized composition that infringes Compl. ¶140

III. The Accused Instrumentality

Product Identification

• The accused instrumentalities are Defendant's proposed generic extended-release tablets of tacrolimus in 0.75 mg, 1 mg, and 4 mg dosages, as described in ANDA No. 221264 ("Defendant's ANDA Products") Compl. ¶1

Functionality and Market Context

• The Defendant's ANDA Products are generic versions of Plaintiff's brand name drug, ENVARSUS XR® Compl. ¶2 The complaint alleges that by filing its ANDA, Defendant has necessarily represented to the FDA that its products have the same active ingredient, dosage form, route of administration, and strengths as ENVARSUS XR® Compl. ¶32
• The ANDA Products are also represented as being bioequivalent to ENVARSUS XR® and are intended for the same approved indications, namely the prophylaxis of organ rejection in kidney transplant patients Compl. ¶28 Compl. ¶32 The complaint does not provide probative visual evidence.

IV. Analysis of Infringement Allegations

The complaint alleges infringement under 35 U.S.C. § 271(e)(2)(A), which defines the submission of an ANDA for a drug claimed in a patent as an act of infringement. The complaint does not provide detailed infringement contentions or claim charts.

'239 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of providing immunosuppressive treatment of a patient in need thereof in a once daily regimen, the method comprising orally administering an extended release tacrolimus formulation to said patient,	The complaint alleges that Defendant's ANDA Products are indicated for the same immunosuppressive uses as ENVARSUS XR® and that the product label will instruct physicians and patients on their oral, once-daily administration.	¶32; ¶45	col. 5:6-15
wherein the extended release tacrolimus formulation releases the tacrolimus with a release of at the most 63.5% of the content of the tacrolimus at the 12 hours time point when tested in vitro according to the USP II dissolution test (paddle) or USP I dissolution test (basket) form in a medium at pH 4.5 and comprising 0.005% hydroxypropylcellulose, and a rotation of 50 rpm.	The complaint alleges on information and belief that the ANDA Products and/or their use in accordance with the product label will satisfy this dissolution profile limitation. The complaint does not provide specific dissolution data for the accused product.	¶45	col. 9:30-41

'998 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of providing immunosuppressive treatment of a patient in need thereof in a once daily regimen, the method comprising orally administering an extended release tacrolimus formulation to said patient,	The complaint alleges that Defendant's ANDA Products are indicated for the same immunosuppressive uses as ENVARSUS XR® and that the product label will instruct physicians and patients on their oral, once-daily administration.	¶32; ¶56	col. 13:21-27
wherein the extended release tacrolimus formulation upon oral administration to a mammal in need thereof releases tacrolimus in a controlled manner and exhibits a Cmax that is at the most about 80% of that of Cmax for Prograf® tablets administered under the same conditions.	The complaint alleges on information and belief that the ANDA Products and/or their use in accordance with the product label will satisfy this pharmacokinetic limitation. The complaint does not provide specific Cmax data for the accused product.	¶56	col. 11:50-59

• Identified Points of Contention:
  • Evidentiary Questions: A central issue for the method-of-use patents ('239, '998, '199, '081, '331, '103) will be evidentiary. Does the Defendant's ANDA product, when administered, actually meet the specific dissolution and pharmacokinetic (PK) profile limitations required by the claims? The complaint's allegations are conclusory, and the case will depend on the discovery of technical data from the ANDA filing.
  • Compositional Questions: For the formulation patents ('918, '190, '823, '095), the key question will be whether Defendant's formulation contains the components required by the claims, particularly a "stabilizing agent." The infringement analysis will turn on the specific excipients used in the ANDA product and whether they meet the definition of a stabilizing agent as construed from the patents.
  • Scope Questions: For the method claims, a point of contention may arise regarding the meaning of "under the same conditions" when comparing the Cmax of the accused product to that of Prograf®. The parties may dispute the precise parameters (e.g., patient population, fasting state) required for this comparison.

V. Key Claim Terms for Construction

• The Term: "a release of at the most 63.5% of the content of the tacrolimus at the 12 hours time point when tested in vitro according to the USP II dissolution test (paddle) or USP I dissolution test (basket) form in a medium at pH 4.5 and comprising 0.005% hydroxypropylcellulose, and a rotation of 50 rpm" (from claim 1 of the '239 Patent).
• Context and Importance: This limitation defines the core of the invention of the '239 Patent-a specific, very slow, extended-release profile. The entire infringement case for this patent hinges on whether the accused ANDA product meets this precise numerical and methodological requirement. Practitioners may focus on whether any deviation in the ANDA product's dissolution profile, or any ambiguity in the test methodology itself, creates a non-infringement argument.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent allows for either the USP II (paddle) or USP I (basket) method, providing some flexibility ('239 Patent, col. 9:35-37). The language does not specify other parameters like apparatus volume beyond what is standard, which a party might argue allows for some variation.
  • Evidence for a Narrower Interpretation: The claim is highly specific, reciting the pH, medium composition, and rotation speed ('239 Patent, col. 9:37-41). The specification provides an exemplary dissolution profile in Figure 1 that illustrates this slow release, which could be used to argue that only formulations closely matching this demonstrated profile meet the claim limitation.
• The Term: "stabilizing agent" (from the '190 Patent family).
• Context and Importance: The novelty of the formulation patents ('918, '190, '823, '095) rests on the inclusion of this agent to prevent degradation of tacrolimus. Infringement will depend on whether an excipient in Defendant's formulation is construed as a "stabilizing agent." Practitioners may focus on this term because if Defendant can show its excipients serve other non-stabilizing purposes (e.g., as fillers or binders only), it may avoid infringement.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The '190 Patent specification defines the term broadly as a "pH-regulating pharmaceutical excipient" capable of providing a pH below 7 ('190 Patent, col. 3:23-26). It provides a non-limiting list of suitable agents, including many common organic acids like citric acid and tartaric acid ('190 Patent, col. 3:30-39).
  • Evidence for a Narrower Interpretation: The patent emphasizes the agent's function is to prevent or reduce the formation of specific degradation products, particularly 8-epitacrolimus ('190 Patent, abstract; '190 Patent, col. 3:5-15). A defendant might argue that an excipient must be shown to have this specific stabilizing effect in their formulation, rather than merely being an acid. The abstract and detailed description's focus on preventing formation of "major degradation products" could be used to argue for a functional rather than purely structural definition '190 Patent, abstract

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement for all ten patents-in-suit. Inducement is alleged based on the assertion that Defendant's product labeling will instruct and encourage physicians and patients to administer the ANDA products in a manner that directly infringes the claims (Compl. ¶48; Compl. ¶59). Contributory infringement is alleged on the basis that the ANDA products are especially adapted for an infringing use and have no substantial non-infringing use (Compl. ¶49; Compl. ¶60).
• Willful Infringement: The complaint alleges that Defendant had knowledge of the patents-in-suit prior to filing its ANDA, based at a minimum on the Paragraph IV certifications sent to Plaintiff (Compl. ¶30; Compl. ¶52). The complaint further alleges that the case is "exceptional" and requests attorneys' fees under 35 U.S.C. § 285, which is consistent with an allegation of willful infringement (Compl. ¶53).

VII. Analyst's Conclusion: Key Questions for the Case

• A primary issue will be evidentiary: Does Defendant's proposed generic product actually possess the specific, numerically-limited in vitro dissolution profiles and in vivo pharmacokinetic (PK) parameters (e.g., Cmax relative to Prograf®) required by the asserted method-of-use patents? The case will likely depend on a technical battle over the data contained in the ANDA and subsequent comparative testing.
• A second central question will be one of claim construction and composition: Does an excipient within Defendant's formulation function as a "stabilizing agent" as that term is understood in the context of the formulation patents? The resolution will depend on whether the term is construed structurally (i.e., is it an organic acid?) or functionally (i.e., does it demonstrably prevent tacrolimus degradation?).
• A third key question will be one of induced infringement: Assuming direct infringement by users is proven, does the language of the Defendant's product label provide sufficient encouragement and instruction for physicians and patients to perform the claimed methods, thereby establishing the specific intent required to find Defendant liable for inducing infringement?